

10/031636

FILE 'HOME' ENTERED AT 15:15:16 ON 05 JAN 2004

=> file medline biosis caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY	0.21	TOTAL SESSION	0.21
---------------------	------	------------------	------

FILE 'MEDLINE' ENTERED AT 15:15:44 ON 05 JAN 2004

FILE 'BIOSIS' ENTERED AT 15:15:44 ON 05 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CAPLUS' ENTERED AT 15:15:44 ON 05 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

```
=> s modif#####(10a) 2'-OH(10a)RNA
MISMATCHED QUOTE ' 2'-OH'
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.
```

=> s modif####(10a) 2-OH(10a) RNA
L1 12 MODIF####(10A) 2-OH(10A) RNA

=> s l1 and isolat###
L2 2 L1 AND ISOLAT###

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3 2 DUP REM L2 (0 DUPLICATES REMOVED)

=> d 13 1-2 bib ab

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:881292 CAPLUS

DN 134:39163

TI Isolation of RNA by differential labeling of the ribose moiety with an affinity label

IN Goldsborough, Andrew Simon

PA Cyclone Genome Sciences Ltd., UK

SO PCT Int Appl 71 pp

DO NOT FILE. APP
CODEN: BTXXD3

DT Patent

DI racine
LA English

ENGLISH
EAN CNT 3

FAN.CNT 3
BATT?

PATENT NO.

PI WO 2000075302 A2 20001214 WO 2000-GB1684 20000502
WO 2000075302 A3 20010426

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
 CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, IS,
 ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, NO, NZ, PL, PT, RO, RU, SE, SD,
 SC, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
 ZM, ZW

ROW: ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
GW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK: ES, FI, FR, GB, IR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG: CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001094626 A1 20011213 WO 2000-GB1683 20000502

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,

	CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
EP 1177281	A2 20020206	EP 2000-929666 20000502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1196631	A1 20020417	EP 2000-929665 20000502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2003039985	A1 20030227	US 2001-11495 20011026		
PRAI GB 1999-10154	A 19990430			
GB 1999-10156	A 19990430			
GB 1999-10157	A 19990430			
GB 1999-10158	A 19990430			
WO 2000-GB1683	W 20000502			
WO 2000-GB1684	W 20000502			
AB A method of purifying RNA from a mixt. of nucleic acids including DNA that makes use of the difference in the sugar moiety of the nucleic acid backbone is described. A sample is treated with a reactant capable of covalently modifying the 2'-OH position of the ribose rings of the RNA under conditions so that a proportion of the 2'-OH positions of the ribose rings bear a substituent followed by sepn. of RNA from other contaminants on the basis of a property of the substituent. The use of alkyl groups to modify the backbone of the RNA for capture on a hydrophobic surface, such as a modified agarose, after salting out with ammonium sulfate is demonstrated.				
L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN AN 1998:816043 CAPLUS DN 130:77053				
TI High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)				
IN Janjic, Nebojsa; Gold, Larry				
PA Nextrax Pharmaceuticals, Inc., USA				
SO U.S., 64 pp., Cont.-in-part of U.S. 5,475,096.				
CODEN: USXXAM				
DT Patent				
LA English				
FAN.CNT 125				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI US 5849479	A 19981215	US 1994-233012	19940425	
US 5475096	A 19951212	US 1991-714131	19910610	
EP 786469	A2 19970730	EP 1997-200035	19910610	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
IL 112141	A1 19980405	IL 1991-112141	19910611	
US 5496938	A 19960305	US 1992-964624	19921021	
CA 2169536	AA 19950316	CA 1994-2169536	19940908	
WO 9507364	A1 19950316	WO 1994-US10306	19940908	
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9476865	A1 19950327	AU 1994-76865	19940908	
AU 692469	B2 19980611			
EP 724647	A1 19960807	EP 1994-927409	19940908	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09502354	T2 19970311	JP 1994-508834	19940908	

US	5811533	A	19980922	US	1995-447169	19950519
US	5789163	A	19980804	US	1995-487425	19950607
US	6168778	B1	20010102	US	1997-870930	19970606
US	2003198989	A1	20031023	US	2003-408085	20030403
US	2003176680	A1	20030918	US	2003-409565	20030407
PRAI	US 1990-536428	B2	19900611			
	US 1991-714131	A2	19910610			
	US 1992-964624	A2	19921021			
	EP 1991-912753	A3	19910610			
	IL 1991-98456	A3	19910611			
	US 1993-117991	A	19930908			
	US 1993-134028	A	19931007			
	US 1994-199507	A	19940222			
	US 1994-205515	B2	19940303			
	US 1994-233012	A	19940425			
	US 1994-234997	A	19940428			
	WO 1994-US10306	W	19940908			
	US 1995-409442	A1	19950324			
	US 1995-412110	A1	19950327			
	US 1995-428964	B1	19950425			
	US 1995-447169	A2	19950519			
	US 1995-469609	A1	19950606			
	US 1998-143190	A1	19980827			
	US 1998-156824	B1	19980918			
	US 2000-502344	A1	20000210			
	US 2001-860474	A1	20010518			
	US 2001-37986	A1	20011018			

AB This invention describes the isolation and characterization of binding properties of a set of high-affinity RNA ligands to vascular endothelial growth factor (VEGF). These ligands were selected from an initial pool of about 1014 RNA mols. randomized at thirty contiguous positions. The evolved RNA ligands bind VEGF with affinities in the low nanomolar range. Also described are modified RNA ligands to VEGF. Such modified RNA ligands may be prep'd. after the identification of 2'-OH RNA ligands or by performing SELEX using a candidate mixt. of modified RNAs. For example, 2'-NH₂ pyrimidine RNA ligands to VEGF are described. The present invention includes the method of identifying nucleic acid ligands and ligand sequences to VEGF.

RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

10/031,636

Freeform Search

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
Database:
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term:

Display: Documents in Display Format: Starting with Number 1

Generate: Hit List Hit Count Side by Side Image

<input type="button" value="Search"/>	<input type="button" value="Clear"/>	<input type="button" value="Interrupt"/>
---------------------------------------	--------------------------------------	--

Search History

DATE: Monday, January 05, 2004 [Printable Copy](#) [Create Case](#)

Set Name Query
side by side

Hit Count Set Name
result set

DB=PGPB; PLUR=YES; OP=ADJ

L2 US-20030039985-A1.did. 1 L2

DB=USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

L1 modify\$3 near5 2-OH near5 RNA 1 L1

END OF SEARCH HISTORY